Eli Lilly Soars Past US$1 Trillion as Novo Nordisk Stumbles

Better Buy: Eli Lilly vs. Novo Nordisk

Novo Nordisk is playing catch-up in the GLP-1 race.

Eli Lilly (NYSE: LLY) Surges Ahead Of Novo Nordisk (NYSE: NVO) In The $100 Billion Obesity Drug Race

Eli Lilly and Company (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) have taken their fierce rivalry from pharmacy shelves to a federal courtroom in New Jersey. Novo Nordisk filed suit against Eli Lilly on July 21, accusing its primary rival of false advertising and unfair competition tied to television and digital campaigns for Zepbound and Mounjaro. At the heart of Novo Nordisk’s legal complaint is its claim that Lilly’s promotional campaigns de…

Eli Lilly Soars Past US$1 Trillion as Novo Nordisk Stumbles

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both raised their full-year profit outlooks on the back of explosive demand for GLP-1 weight-loss and diabetes treatments. But by mid-year, Eli Lilly's blockbuster injectable drugs propelled its valuation past US$1 trillion, while Novo Nordisk shares have slid 8 percent year-to-date as the company grapples with slowing US sales and an overwhelming reliance on a single therapeutic categ…